Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
Date:8/16/2010

latory approval for Caldolor in South Korea, and in April 2010 submitted a New Drug Application to the Korean Food and Drug Administration. Following potential approval, DB Pharm Korea will handle ongoing regulatory reporting, product marketing, distribution and sales in the territory. Cumberland maintains responsibility for product formulation, development and manufacturing and will provide finished product for sale. In exchange for the license to the product, Cumberland will receive upfront and milestone payments as well as royalties on future sales.

License Agreement for Caldolor in Canada

In April 2010, Cumberland entered into an exclusive agreement with Alveda Pharmaceuticals Inc., a Toronto-based specialty pharmaceutical company, for commercialization of Caldolor in Canada. Under the agreement, Alveda will seek Canadian regulatory approval for Caldolor and will handle ongoing regulatory requirements, product marketing, distribution and sales upon potential approval. Cumberland will maintain responsibility for product formulation, development and manufacturing and will receive royalties on any sales in addition to upfront and milestone payments.

Share Repurchase ProgramIn May 2010, Cumberland's Board of Directors approved a share repurchase program that authorized the Company to repurchase up to $10 million of its outstanding common shares. During the second quarter, Cumberland repurchased approximately 200,000 shares pursuant to this program at an average price of $6.86 per share. Purchases may continue to be made from time-to-time on the open market over a period of several months. The Company continues to believe that its shares are currently undervalued and that they represent an attractive investment.

RECENT DEVELOPMENTSSubmission of New Drug Application for Caldolor in Australia

In August 2010, Phebra submitted a New Drug Application to the Therapeutics Goods Administration for regulatory approval o
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
2. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
3. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
4. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
5. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
6. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
7. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
8. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
9. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
10. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
11. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... , Nov. 23, 2014  Aurobindo Pharma ... of Gabapentin Capsules, USP 300 mg 100-count bottles to ... to contain some empty capsules. Empty capsules ... adverse health consequences that could range from no effect, ... or status epilepticus (long period seizures) that could be ...
(Date:11/22/2014)... -- New data demonstrates that flibanserin, a novel, non-hormonal medicine ... sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does not ... women when taken at bedtime. The data was presented ... America,s (SMSNA) 20th Annual Fall Scientific Meeting ... SMSNA accepted this study as a late breaking abstract ...
(Date:11/22/2014)... , 21 de noviembre de 2014  BioClinica®, ... clínicos externalizados y tecnologías eClinical, ha indicado un ... ,seguimiento inteligente, para el seguimiento basado en el ... amplía el concepto del seguimiento basado en el ... las visitas de seguimiento o cambio de los ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... Today Novo Nordisk announced results of its ... treatment with NovoLog® (insulin aspart [rDNA origin] injection). The ... Scientific Sessions, demonstrated a reduction of A1c levels in ... was introduced at meals, using two approaches that start ...
... Reportlinker.com announces that a new market research report is available in its catalogue: , ... Global Melanoma Therapeutics industry , ... http://www.reportlinker.com/p0197206/Global-Melanoma-Therapeutics-industry.html , , , ... markets for Melanoma Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, ...
Cached Medicine Technology:Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients 2Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients 3Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients 4Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients 5Study Shows Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients 6Global Melanoma Therapeutics Industry 2Global Melanoma Therapeutics Industry 3Global Melanoma Therapeutics Industry 4Global Melanoma Therapeutics Industry 5Global Melanoma Therapeutics Industry 6Global Melanoma Therapeutics Industry 7Global Melanoma Therapeutics Industry 8Global Melanoma Therapeutics Industry 9Global Melanoma Therapeutics Industry 10Global Melanoma Therapeutics Industry 11Global Melanoma Therapeutics Industry 12
(Date:11/24/2014)... 2014 The Mesothelioma Applied Research ... International Symposium on Malignant Mesothelioma from March 2nd through ... sessions will take place on the campus of the ... a community dinner and an awards ceremony, will be ... cover a range of topics about pleural and peritoneal ...
(Date:11/24/2014)... UK (PRWEB) November 24, 2014 ... Massaggi , London's pre-eminent pain-relief service and massage ... Emmett Sports Massage (ESM). This newest sports ... , The key difference between traditional sports massage ... to access the body's very own "reset button,” ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection ... the company is a leading online supplier in the international ... available at discounted prices, up to 30% off. , “We ... This time, all of our items are offered at low ... so I have confidence in our fresh assortment. You will ...
(Date:11/24/2014)... Philadelphia, PA (PRWEB) November 24, 2014 ... care coordination and disease management services to health ... to implement Essette’s Medical Management software suite. ... SaaS platform in a program to reduce patients' ... includes Population Health Management, Care Management, Utilization Management, ...
(Date:11/23/2014)... 24, 2014 The clinical trial ... provides data on the Aspergillosis clinical trial scenario. ... to the clinical trials on Aspergillosis. It includes ... recruitment status as per the site of trial ... preliminary coverage of disease clinical trials by their ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... March 7 The rheumatoid arthritis (RA),treatment market, held ... withdrawal of Vioxx and Bextra, is rebounding due to ... to,treat RA topped $12 billion in 2006 and -- ... over 11% a year through 2011,according to a new ...
... March 7 Universal,Health Realty Income Trust (NYSE: ... of,Trustees voted to pay a dividend of $.58 ... record as of March 17, 2008., Universal ... trust,invests in healthcare and human service related facilities ...
... research and teaching at ... the Medical Center, COLUMBUS, Ohio, ... over the last six years accounting,for nearly 50 percent of the region,s ... employers reduced jobs, says an economic,impact report released today by the Columbus ...
... Va.--Dr. X.J. Meng, of Blacksburg, Va., a professor of ... Department of Biomedical Sciences and Pathobiology at Virginia Tech, ... million from the National Institutes of Health (NIH) to ... of the work is to develop a vaccine to ...
... on a cells ability to roll along a surface, MIT ... kinds of cells a process that could result in ... in remote locations. , Rohit Karnik, an MIT assistant professor ... the new finding appearing this week in the journal Nano ...
... of developmental neurobiology at the Medical College of Georgia ... received the 2008 Mathilde Solowey Lecture Award in Neurosciences. ... Advanced Education in the Sciences, honors young or rising ... translational and of broad importance. , Dr. Mei will ...
Cached Medicine News:Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 3Health News:Human, animal vaccine development goal of hepatitis E virus research 2Health News:Human, animal vaccine development goal of hepatitis E virus research 3Health News:On a 'roll': MIT researchers devise new cell-sorting system 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3
... for the precise requirements of blood ... Blood Bank Equipment meets American Association ... Red Cross (ANRC) and U.S. Food ... storage freezers, and platelet incubators feature ...
... Designed for the precise requirements ... Thermo Forma Blood Bank Equipment meets ... American National Red Cross (ANRC) and ... standards. Refrigerators, storage freezers, and platelet ...
Refrigerator specially designed for the storage of blood in standard 500ml bags, complying with Australian Standard AS3864 1997....
The Testosterone Enzyme Immunoassay is intended for the quantitative determination of Testosterone concentration in human serum. No special pretreatment of the sample is necessary. For in vitro Diag...
Medicine Products: